Augmenting vaccine efficacy against delta variant with 'Mycobacterium-w' mediated modulation of NK-ADCC and TLR-MYD88 pathways

Fifty healthcare workers (HCW) who had received Mycobacterium-w (Mw) and at least one dose of ChAdOx1 nCoV-19 vaccine subsequently (Mw+ChAdOx1 group) were monitored for symptomatic COVID-19, during a major outbreak with the delta variant of SARS-CoV-2 (April-June, 2021) in India, along with 201 HCW receiving both doses of the vaccine without Mw (ChAdOx1 group). Bulk RNA-Seq analysis was carried out on 4 subjects enrolled from each group. Overall design: Comparative gene expression analysis between 4 subjects from Mw + ChAdOx1 and ChAdOx1 group.